Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DC1s-CTL Cell Therapy to Treat Patients With Renal Cell Carcinoma After Radical Resection

NCT02787915 is registered in ClinicalTrials.gov with Xuzhou Medical University as lead sponsor.

NCT NCT02787915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02787915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DC1s-CTL Cell Therapy to Treat Patients With Renal Cell Carcinoma After Radical Resection
Lead sponsor
Xuzhou Medical University
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 30, 2016
Completion date
August 31, 2019
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma